Objective: Τhe study aimed to study the rate of atypical squamous cells of undetermined significance (ASCUS) that progressed to high-grade squamous intraepithelial lesions (HGSIL), as well as the number of patients who finally necessitated a surgical intervention during follow-up. Methods: A prospective study was conducted on patients admitted for colposcopy during 2007-2012. We exclusively included those who presented with newly ASCUS diagnosis, while patients with a history of cervical intraepithelial neoplasia (CIN) were excluded. Primary end points were the cumulative rate of HGSIL during follow-up and the rate of surgical procedures performed because of such lesions. Results: There were 134 ASCUS cases included. Overall, there were 48 (35.8%) surgical excision procedures performed to treat or eliminate HGSIL during the follow-up period. According to the final histopathology of surgical specimens, the cumulative rate of CIN2 or higher cervical lesions was 28.4% (n = 38). Conclusion: The cumulative rate of CIN2+ during follow-up period was almost 30% for patients with ASCUS, with the necessity for interventional treatment being even higher.

Keywords:
Atypical squamous cells of undetermined significance, Cervical intraepithelial neoplasia, High-grade squamous intraepithelial lesion, Loop electrosurgical excision procedure
1.
Eltabbakh GH, Lipman JN, Mount SL, Morgan A: Significance of atypical squamous cells of undetermined significance on ThinPrep papanicolaou smears. Gynecol Oncol 2000;79:44-49.
2.
The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses. National cancer institute workshop. JAMA 1989;262:931-934.
3.
Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Borgatta L, Buck H, Kramer L, Rubin R: Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-134.
4.
Eskridge C, Begneaud WP, Landwehr C: Cervicography combined with repeat papanicolaou test as triage for low-grade cytologic abnormalities. Obstet Gynecol 1998;92:351-355.
5.
Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ: Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-954.
6.
Fanny L, Orlando Q, Trinidad B, Estefanía L: Follow-up of women with ASCUS in Chile. Diagn Cytopathol 2011;39:258-263.
7.
ASCUS-LSIL Traige Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-1392.
8.
Pedrosa M, Mattos I, Koifman R, Silva R, Ataide M: Atipias escamosas de significado indeterminado: uma revisão da literature. DST J Bras Doencas Sex Transm 2003;15:46-51.
9.
Becker E Jr, Edelweiss MI, Nonnenmacher B, Bozzetti MC: Prevalence and epidemiologic correlates of atypical squamous cells of undetermined significance in women at low risk for cervical cancer. Diagn Cytopathol 2001;24:276-282.
10.
Emerson RE, Puzanov A, Brunnemer C, Younger C, Cramer H: Long-term follow-up of women with atypical squamous cells of undetermined significance (ASCUS). Diagn Cytopathol 2002;27:153-157.
11.
Tropé A, Sjøborg KD, Nygård M, Røysland K, Campbell S, Alfsen GC, Jonassen CM: Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012;50:1927-1935.
12.
Gupta S, Sodhani P, Chachra KL, Singh V, Sehgal A: Outcome of ‘atypical squamous cells' in a cervical cytology screening program: implications for follow up in resource limited settings. Diagn Cytopathol 2007;35:677-680.
13.
Yarandi F, Izadi Mood N, Mirashrafi F, Eftekhar Z: Colposcopic and histologic findings in women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Aust N Z J Obstet Gynaecol 2004;44:514-516.
14.
Piacentini P, Mamprin R, Cumino S, Mirkin A: Correlacion y Seguimiento Colpo-Viro-Histologico de Pacientes con Diagnostico Citologico de Ascus. Buenos Aires, XXVI Congreso Internacional de Obstetricia y Ginecología SOGIBA, 2008.
15.
Yang M, Zachariah S: ASCUS on cervical cytologic smears. Clinical significance. J Reprod Med 1997;42:329-331.
16.
Stastny JF, Remmers RE, London WB, Pedigo MA, Cahill LA, Ryan M, Frable WJ: Atypical squamous cells of undetermined significance: a comparative review of original and automated rescreen diagnosis of cervicovaginal smears with long term follow-up. Cancer 1997;81:348-353.
17.
Pitman MB, Cibas ES, Powers CN, Renshaw AA, Frable WJ: Reducing or eliminating use of the category of atypical squamous cells of undetermined significance decreases the diagnostic accuracy of the Papanicolaou smear. Cancer 2002;96:128-134.
18.
Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P: Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007;109:1325-1331.
19.
Songveeratham S, Kietpeerakool C, Khunamornpong S, Sribanditmongkol N, Srisomboon J: Preceding cervical cytology in women with high-grade squamous intraepithelial lesion. Arch Gynecol Obstet 2011;283:1381-1384.
20.
Budal EB, Haugland HK, Skar R, Maehle BO, Bjørge T, Vintermyr OK: HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway. Cancer Med 2014;3:182-189.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.